Axogen, Inc. AXGN

Set alert

Price alert · AXGN

All alert types
49.85 USD 0.00 0.00%

At close

50.50 +0.65 +1.30%

Pre-market · Nov 3, 9:04 AM ET

Bid
49.85 × 1
Ask
49.86 × 1
49.04 Day range 50.54
22.92 52-week range 52.91
YTD
+52.31%
1 year
+114.41%
Open
49.46
Prev close
49.85
Mkt cap
2.98B
Vol
1.96M
Avg vol
1.39M
EPS
-0.63
P/E
0.00
Div yield
0.00%
More statistics
Low
49.04
High
50.54
Forward P/E
70.67
Beta
1.15
Short ratio
3.57
Inst. own
95.99%
Dividend
0.00
Ex-div date
Jan 26, 2010
Earnings
Feb 23, 2027
50-d avg
42.86
200-d avg
39.57
1y target
59.09

5Y chart

Chart tools
Interval

Events in this range
  • Oct 29, 2025Earnings: 0.12; estimate 0.09; surprise 33.33%
  • Feb 24, 2026Earnings: 0.07; estimate 0.08879; surprise -21.16%
  • Apr 28, 2026Earnings: 0.07; estimate 0.12; surprise -41.67%
  • Jul 29, 2026Earnings: 0.12; estimate 0.1214; surprise -1.15%
  • Oct 28, 2026Earnings: 0.21; estimate 0.1313; surprise 59.94%
  • Oct 29, 2026Rating: HC Wainwright & Co. · Buy → Buy
  • Oct 29, 2026Rating: Wells Fargo · Overweight → Overweight
  • Oct 29, 2026Rating: Truist Securities · Buy → Buy
  • Oct 29, 2026Rating: Barclays · Overweight → Overweight
  • Oct 29, 2026Rating: Leerink Partners · Outperform → Outperform
  • Oct 29, 2026Rating: Canaccord Genuity · Buy → Buy
Signals (78)
NameDateAgo
SMA: BullishOct 26, 20261 week ago
SMA: BullishOct 26, 20261 week ago
SMA: BearishSep 28, 20261 month ago
SMA: BearishSep 7, 20261 month ago
MACD: Sell SignalSep 7, 20261 month ago
RSI: OverboughtAug 24, 20262 months ago
MACD: Buy SignalAug 17, 20262 months ago
SMA: BullishAug 3, 20263 months ago
SMA: BearishJul 6, 20264 months ago
MACD: Sell SignalJul 6, 20264 months ago
MACD: Buy SignalApr 20, 20266 months ago
SMA: BullishApr 13, 20266 months ago
SMA: BearishApr 6, 20267 months ago
SMA: BullishMar 30, 20267 months ago
SMA: BearishFeb 23, 20268 months ago
MACD: Sell SignalFeb 23, 20268 months ago
RSI: OverboughtJan 26, 20269 months ago
RSI: OverboughtOct 27, 20251 year ago
SMA: BullishOct 13, 20251 year ago
SMA: BearishOct 6, 20251 year ago

Newest 20 of 78.

Key statistics

Market cap
2.98B
Enterprise value
2.62B
Trailing P/E
0.00
Forward P/E
70.67
PEG ratio
99.04
Price / sales
11.16
Price / book
6.00
EPS (TTM)
-0.63
Beta
1.15
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-11.96%
Revenue (TTM)
266.93M
Revenue growth
26.20%
Free cash flow
29.81M
Total cash
348.07M
Total debt
19.47M
Return on equity
-10.35%
Shares outstanding
59.73M
Short % of float
9.76%
50-day average
42.86
200-day average
39.57

Financials — quick view

All financials
AXGN Revenue — quarterly 75.83M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
AXGN Net income — quarterly 2.33M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
AXGN EPS — quarterly 0.04
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

AXGN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 23, 2027Dec 30, 20260.15———
Oct 28, 2026Sep 30, 20260.13130.21+0.08+59.94%
Jul 29, 2026Jun 30, 20260.12140.120.00-1.15%
Apr 28, 2026Mar 31, 20260.120.07-0.05-41.67%
Feb 24, 2026Dec 31, 20250.088790.07-0.02-21.16%
Oct 29, 2025Sep 30, 20250.090.12+0.03+33.33%

Upgrades / downgrades

AXGN analyst upgrades and downgrades
DateFirmActionFromTo
Oct 29, 2026Canaccord GenuitymainBuyBuy
Oct 29, 2026Leerink PartnersmainOutperformOutperform
Oct 29, 2026BarclaysmainOverweightOverweight
Oct 29, 2026Truist SecuritiesmainBuyBuy
Oct 29, 2026Wells FargomainOverweightOverweight
Oct 29, 2026HC Wainwright & Co.mainBuyBuy

About Axogen, Inc.

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on AXGN — it syncs with the Stock Master app.

Insider holders

AXGN insider holders
InsiderRelationLatest transactionDateShares held
BEGAN MARC A.General CounselConversion of Exercise of derivative securityFeb 26, 202650,135
DALE MICHAEL DChief Executive OfficerSaleDec 9, 202563,537
DEVINNEY ERICK WAYNEOfficerSaleMar 15, 2026262,781
HARTLEY LINDSEY MARIEChief Financial OfficerSaleMay 6, 202665,146
KEMP JENS SCHROEDEROfficerSaleMay 6, 202672,451
LEVINE ALAN M.DirectorConversion of Exercise of derivative securityJun 17, 202650,893

Institution ownership

AXGN institution ownership
Holder% heldSharesValueReported
Blackrock Inc.7.40%4,419,208220.32MJun 29, 2026
Morgan Stanley4.60%2,747,924137.00MJun 29, 2026
First Light Asset Management, LLC4.60%2,748,361137.02MJun 29, 2026
Vanguard Capital Management LLC3.78%2,257,948112.57MJun 29, 2026
Artemis Investment Management Llp2.98%1,780,99288.79MSep 29, 2026
Polar Capital Holdings PLC2.51%1,500,82274.82MJun 29, 2026

Fund ownership

AXGN fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.67%1,596,14979.58MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.31%1,380,75668.84MSep 29, 2026
Manager Directed Portfolios-Hood River Small-Cap Growth Fund1.83%1,095,48254.62MJul 30, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.02%609,72830.40MJun 29, 2026
T. Rowe Price New Horizons Fund, Inc.0.98%588,20029.32MJun 29, 2026
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund0.96%575,48128.69MJul 30, 2026